Novavax (NASDAQ: NVAX) shares edged down 0.6% to $9.00 in midday trading on Friday, August 28, 2026, following the announcement that its updated Nuvaxovid vaccine received regulatory clearance in the United States, European Union, and Japan. The modest price movement suggests investors are focusing more on commercial uptake than the regulatory milestone itself.
The approvals cover the XFG-adapted formulation of the protein-based vaccine, which is designed to target the currently dominant XFG variant. With these clearances, Novavax transitions further into a partner-driven commercialization model, leaning heavily on Sanofi (NASDAQ: SNY) and Takeda to drive sales and generate royalty revenue.
Royalty Structure and Revenue Outlook
Under the existing agreement, Sanofi leads commercialization of Nuvaxovid in most major markets, and Novavax stands to receive royalties ranging from the high teens to the low twenties percentage of Sanofi's worldwide net sales. This arrangement keeps Novavax's selling costs low but reduces its direct influence over demand. Sanofi is currently expanding its U.S. presence and rolling out launches in Germany, Canada, and other markets.
Importantly, Novavax's adjusted 2026 revenue guidance of $235 million to $275 million does not include any royalties or milestone payments associated with Sanofi. This means any revenue from Sanofi sales would be incremental to current forecasts, potentially providing upside if commercial uptake is strong.
Japan Market Performance
In Japan, Takeda markets Nuvaxovid, and Novavax reported that the vaccine was the second most used in the country during the 2025-2026 season, with higher delivery volumes and more vaccination sites involved. This suggests a solid foothold in a key international market, though the overall competitive landscape remains intense.
Competitive Landscape
The FDA has cleared updated vaccines from Novavax-Sanofi, Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE)-BioNTech, all formulated to protect against the leading XFG variant. Nuvaxovid remains the only protein-based option among the three, utilizing Novavax's Matrix-M adjuvant and available in pre-filled syringes requiring cold storage at 2°C to 8°C.
Moderna shares were down 4.0% to $137.12, while Pfizer slipped 0.3% to $27.93. Sanofi ADRs traded flat at $44.82.
Financial Highlights and Risks
Novavax reported second-quarter revenue of $57 million, a 76% decline compared to the prior-year period, which included significant milestone payments. Product sales increased 76% to $19 million, and the company held $724 million in cash. The company anticipates providing commercial supply to Sanofi for the upcoming season, and a scheduled manufacturing transfer in mid-2027 could trigger an additional $75 million milestone payment.
Analyst sentiment is mixed, with the latest four ratings comprising two buys, one hold, and one sell. Price targets range from $7 to $19, reflecting uncertainty about demand and partner execution. Key risks include seasonal demand fluctuations, insurance coverage dynamics, and the performance of commercialization partners. Novavax has not provided a sales outlook from Sanofi, leaving investors to monitor disclosed partner sales and resulting royalty revenue as the next key indicator.
While regulatory approvals remove a significant hurdle, the market's muted reaction underscores the challenges ahead. The company's shift to a partner-based model reduces operational risk but also limits its control over market outcomes. As the season progresses, royalty reports will be crucial in determining whether Novavax can translate approvals into sustained financial performance.
